Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | OGG1 | O15527 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 2/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29927069 | 1.00 | ADRA1D (0.47) | ADRA1DTRPM8HPGDALOX15PARP1 | |
| SCHEMBL24729465 | 1.00 | ADRA1D (0.47) | ADRA1DTRPM8HPGDALOX15PARP1 | |
| SCHEMBL27480876 | 0.85 | HPGD (0.46) | ADRA1DTRPM8HPGDALOX15AOC3 | |
| SCHEMBL29141742 | 0.83 | ADRA1D (0.39) | ADRA1DTRPM8HPGDALOX15AOC3 | |
| SCHEMBL3424145 | 0.81 | PARP1 (0.46) | TRPM8PARP1AOC3ACP3 | |
| SCHEMBL3715003 | 0.81 | ADRB1 (0.50) | PARP1ADRB2ADRB1ADRB3 | |
| SCHEMBL27997344 | 0.81 | HPGD (0.43) | ADRA1DHPGDALOX15AOC3ACP3 | |
| SCHEMBL515036 | 0.80 | PARP1 (0.44) | HPGDPARP1 | |
| SCHEMBL27405841 | 0.80 | PARP1 (0.44) | ADRA1DTRPM8HPGDALOX15PARP1 | |
| SCHEMBL27469165 | 0.80 | PARP1 (0.44) | ADRA1DTRPM8HPGDALOX15PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4308227-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197755-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197755-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2016095088-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK4 | ADRA1D 2135/4885TRPM8 1879/4885HPGD 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.